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Abstract  59 
 60 
Purpose: To assess the case-finding performance of the Frequency Doubling 61 
Technology perimeter (FDT), Moorfields Motion Displacement Test (MMDT), 62 
iVue Optical Coherence Tomographer (OCT) and Ocular Response Analyser 63 
(ORA), used alone or combined, for suspect and definite primary open angle 64 
glaucoma (POAG).  65 
 66 
Design: Cross-sectional, observational, community-based study. 67 
 68 
Participants: 505 subjects aged 60 years and older recruited from a community 69 
setting using no pre-defined exclusion criteria. 70 
 71 
Methods: Subjects underwent 4 index tests conducted by a technician 72 
unaware of subjects’ ocular status. FDT and MMDT were used in 73 
suprathreshold mode. iVue OCT measured ganglion cell complex and retinal 74 
nerve fibre layer (RNFL) thickness. The reference standard was a full 75 
ophthalmic examination by an experienced clinician, masked to index test 76 
results. Subjects were classified as POAG (open drainage angle, 77 
glaucomatous optic neuropathy, and glaucomatous field defect), glaucoma 78 
suspect, ocular hypertension (OHT) or non-POAG/non-OHT.  79 
 80 
Main Outcome Measures: Test performance evaluated the individual as unit of 81 
analysis. Diagnostic accuracy was initially assessed using predefined cut-offs 82 
for abnormality to generating sensitivity, specificity, and likelihood ratios. 83 
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Continuous data were used to derive estimates of sensitivity at 90% specificity, 84 
and partial area under the curve of receiver operating characteristic (AUROC) 85 
plots from 90% to 100% specificity.  86 
 87 
Results: From the reference standard examination, 26 (5.1%) subjects were 88 
POAG and 32 (6.4%) glaucoma suspects. Sensitivity (95% confidence interval) 89 
at 90% specificity for detection of glaucoma suspect/POAG combined was 90 
41% (28 to 55) for FDT, 35% (21 to 48) for MMDT, and 57% (44 to 70) for 91 
best-performing OCT parameter (inferior quadrant RNFL thickness); for POAG, 92 
sensitivity was 62% (39 to 84) for FDT, 58% (37 to 78) for MMDT, and 83% (68 93 
to 98) for inferior quadrant RNFL thickness. The partial AUROC was 94 
significantly greater for inferior RNFL thickness than visual-function tests 95 
(p<0.001). Post-test probability of glaucoma suspect /POAG combined and 96 
definite POAG increased substantially when best-performing criteria were 97 
combined for FDT or MMDT, iVue OCT and ORA. 98 
 99 
Conclusions: Diagnostic performance of individual tests gave acceptable 100 
accuracy for POAG detection. The low specificity of visual-function tests 101 
precludes their use in isolation, but case-detection improves by combining 102 
RNFL thickness analysis with visual-function tests.  103 
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Open angle glaucoma (OAG) is a major cause of visual morbidity, accounting 104 
for 10.6% to 13.5% of blindness in high-income countries.1 However, 105 
epidemiological studies in developed countries consistently demonstrated that 106 
approximately half of those with OAG remained undetected using current case-107 
finding strategies. 2-8 108 
 109 
OAG satisfies Wilson-Jungner criteria for the condition and treatment ideally 110 
required to initiate a screening programme.9 In 2012, a Comparative 111 
Effectiveness Review by the Agency for Healthcare Research and Quality 112 
concluded that limited evidence existed on the effectiveness of screening for 113 
OAG in adult populations.10 An earlier UK-based economic modelling study 114 
reported that population screening at any age was not cost-effective, but 115 
stronger evidence existed in support of targeted screening of high-risk 116 
groups.11 A strategy for improving screening cost-effectiveness was proposed, 117 
involving initial technology-based assessment, allowing an enriched population 118 
to be referred for office-based assessment by an ophthalmologist or 119 
optometrist. In the context of case-finding for a low prevalence disease in the 120 
general population, an ideal screening test must be simple, fast and combine 121 
high specificity (above 90%), with acceptably high sensitivity. However, a 2008 122 
systematic review found no single test, used alone or in combination, provided 123 
sufficiently high accuracy for OAG detection.12 The review highlighted a dearth 124 
of high-quality diagnostic accuracy studies for OAG detection. In many cases, 125 
reliability and applicability of study findings are limited by methodology, with 126 
failure to satisfy the quality assessment of diagnostic accuracy studies 127 
(QUADAS) criteria.13 128 
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 129 
This study aims to determine diagnostic accuracy of modern imaging and  130 
visual function testing technologies, used alone and in combination, for 131 
detecting OAG in a representative sample of the primary-care population, 132 
compared to a reference standard ophthalmic examination including standard 133 
automated perimetry (SAP). The study was designed, and findings reported in 134 
accordance with Standards for Reporting of Diagnostic Accuracy (STARD) 135 
criteria.14   136 
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Methods 137 
This prospective cross-sectional study was conducted in one university-based 138 
community eye clinic in London, UK, during 12 months from September 2012. 139 
The study was approved by the institutional review board and adhered to the 140 
Declaration of Helsinki tenets. All subjects provided written informed consent. 141 
Males and females aged 60 years and older were recruited. Study information, 142 
together with an invitation to participate, was distributed locally through 143 
neighbouring optometry practices and community groups. To ensure a 144 
representative sample of the eligible population, no pre-defined exclusion 145 
criteria were specified; subjects with known POAG or other ocular morbidities 146 
were included.  147 
 148 
All subjects underwent a series of technology-based index tests, followed by a 149 
reference standard ophthalmic examination on the same day. Figure 1 shows 150 
the study flow diagram. Thresholds of abnormality for the index tests were 151 
based on cut-offs commonly reported in previous literature, manufacturers’ 152 
suggested cut-offs, and comparisons with internal normative databases, and 153 
were specified in the protocol prior to data analysis. The technology-based 154 
assessment comprised four index tests and was performed by a single, 155 
experienced technician with no prior knowledge of subjects’ ocular status or 156 
findings from the reference standard ophthalmic examination. All equipment 157 
used for tests performed during the reference standard ophthalmic 158 
examination and technology-based assessment was calibrated daily in 159 
accordance with manufacturers’ instructions, and examinations were 160 
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undertaken in dedicated research rooms based in the community eye clinic to 161 
ensure a consistent and reliable testing environment over the 12-month period. 162 
 163 
Visual function tests (FDT and MMDT) 164 
The first generation frequency doubling technology (FDT; Carl Zeiss Meditec, 165 
Inc., Dublin, CA) perimeter was used in C20-5 suprathreshold mode (software 166 
version 4.00.0). Contrast thresholds are evaluated at 17 locations within the 167 
central 20⁰ of visual field. A detailed description of measurement principles has 168 
been described elsewhere.15 An abnormal result was defined using two cut-169 
offs: a) one or more location(s) missed at the p<5% significance level and b) 170 
one or more location(s) missed at the p<1% significance level. Further analysis 171 
was performed using a scoring system described by Patel et al. which 172 
allocates an overall score between 0 and 87 for each FDT result, giving 173 
increased importance to more severe defects and locations missed closer to 174 
fixation.16   175 
 176 
The Moorfields motion displacement test (MMDT; Moorfields Eye Hospital, 177 
London, UK) is a prototype perimeter based on a form of temporal hyperacuity, 178 
in which subjects identify oscillation of a vertical bar, the threshold being the 179 
smallest displacement seen. Testing was performed using the Enhanced 180 
Standard Threshold Algorithm (ESTA) 99.5 suprathreshold program (Pandora, 181 
software version v1.7.10) (see http://www.moorfieldsmdt.co.uk/clinicians.asp 182 
for more details on MMDT technology). The test presents 31 stimuli on a 183 
standard laptop LCD display. Displacements seen or not seen are recorded on 184 
a pass-fail plot, and this information is used together with the ESTA spatial 185 
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filter to generate a probability plot that provides an estimate of the ‘probability 186 
of true damage’ (PTD) between 0 and 100 at each test location. In the present 187 
study, an abnormal plot was defined by the developers’ recommended 188 
threshold of a global PTD 3.0.   189 
 190 
The testing order between FDT and MMDT was randomized, and these 191 
examinations were never performed in immediate succession. Tests were 192 
repeated once if one or more locations were missed, or if the result was 193 
unreliable (Table 1, available at www.aaojournal.org). 194 
 195 
iVue Spectral Domain OCT (SD-OCT) 196 
The iVue optical coherence tomographer (OCT; Optovue Inc., Fremont, CA) is 197 
a compact version of the RTVue OCT. Diagnostic data for OAG detection were 198 
obtained using the ganglion cell complex (GCC) protocol of the iWellness 199 
scan, and glaucoma optic nerve head (ONH) retinal nerve fibre layer (RNFL) 200 
scan patterns in software version V3.2.0.42 (details of scan protocols are 201 
described elsewhere17). Scans were initially captured through undilated pupils 202 
in dark-room illumination, and repeated following pupil dilation if data quality 203 
failed to meet manufacturers’ guidelines (8%, 81 of 1009 eyes).  204 
 205 
Of the structural parameters for GCC and RNFL thickness, the overall mean, 206 
superior hemifield and inferior hemifield thickness were analysed. RNFL 207 
thickness was further evaluated by hourglass quadrant: temporal 316 to 45 208 
degrees, superior 46 to 135 degrees, nasal 136 to 225 degrees, and inferior 209 
226 to 315 degrees. GCC thickness data were also represented by two 210 
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additional parameters which analyse the pattern of GCC loss using differing 211 
levels of focality: Global loss volume (GLV) and Focal loss volume (FLV). 212 
Descriptions of procedures deriving these parameters have been reported 213 
previously.18-20 The defined cut-off for abnormality was any RNFL or GCC 214 
parameter falling outside the 99% normal limit based on manufacturers’ 215 
integrated normal database.   216 
 217 
Ocular response analyzer (ORA) 218 
The ORA (Reichert Ophthalmic Instruments, Depew, NY, USA) is an air-puff 219 
tonometer which uses a bi-directional applanation sequence to derive two 220 
measures of corneal biomechanical properties: corneal hysteresis (CH) and 221 
corneal resistance factor (CRF), and two intraocular pressure (IOP) 222 
parameters: IOPg (Goldmann-correlated) and IOPcc (Cornea-compensated).21 223 
A minimum of four measurements from each eye was acquired (software 224 
version 3.01). The highest waveform score (WS) measurement was used for 225 
analysis provided multiple measurements with similar graphical outputs had 226 
been attained22 with a WS of 3.5 or greater.22, 23 IOPg or IOPcc above 227 
21mmHg was defined as the cut-off for abnormality.     228 
 229 
Reference standard ophthalmic examination 230 
All subjects underwent a series of standard tests for glaucoma by an 231 
experienced clinician, trained and validated in glaucoma according to UK 232 
practice, and masked to results of the preceding index tests. Validation of the 233 
reference standard examiner was confirmed by competency-based 234 
assessment, with results being compared with classification by a consultant 235 
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glaucoma sub-specialist ophthalmologist. Kappa agreement for combined and 236 
separate assessment of the optic disc and visual field ranged from 0.70 to 237 
0.89.   238 
 239 
Visual field testing was performed with the Humphrey Field Analyzer (HFA; 240 
Carl Zeiss Meditec, Inc., Dublin, CA) and the Swedish Interactive Thresholding 241 
Algorithm (SITA) 24-2 standard pattern (Model 720i, software version 5.1.2). 242 
Where possible, HFA was repeated for unreliable results (false negative 243 
responses or fixation losses >33%, false positive responses >15%) and 244 
Glaucoma hemifield test (GHT) recordings of ‘outside normal limits’. Following 245 
full anterior segment assessment by biomicroscope, and measurement of IOP 246 
by Goldmann Applanation Tonometer, eyes with a potentially occludable angle 247 
identified by the van Herick test24 were evaluated by gonioscopy. Detailed 248 
posterior segment examination was performed through dilated pupils using 249 
indirect ophthalmoscopy and fundus photography (Topcon TRC-NW8F). 250 
Subjects were asked to complete a questionnaire regarding the acceptability of 251 
each index test.  252 
 253 
The following criteria were used for classification of subjects as definite POAG 254 
or as glaucoma suspect based on observations from one or both eyes: 255 
• Definite POAG: open anterior chamber angle, presence of glaucomatous 256 
optic neuropathy (either localised absence of neuro-retinal rim, cup/disc 257 
ratio (CDR) of 0.7 or inter-ocular asymmetry in vertical CDR of 0.2 in 258 
similar sized discs) and the presence of a concordant glaucomatous field 259 
defect based on criteria amended from Anderson and Patella25 (a cluster of 260 
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3 points on the pattern deviation plot having p<5% with at least one point 261 
with p<1%, none of which can be edge points unless located immediately 262 
above or below the nasal horizontal meridian, AND pattern standard 263 
deviation (PSD) p<5%, AND GHT ‘outside normal limits’).  264 
 265 
• Glaucoma suspect: included ‘disc suspects’ showing features of 266 
glaucomatous optic neuropathy but with normal or equivocal fields, and 267 
subjects with visual field defects but without concordant disc damage (see 268 
‘Definite POAG’ above for definitions of glaucomatous optic neuropathy 269 
and visual field defects). 270 
 271 
The ocular hypertension (OHT) case definition in this study for subjects not 272 
taking IOP-lowering medication was based on measurement of IOP above 273 
21mmHg on two separate occasions, with open anterior chamber angles and 274 
neither visual field plots nor optic discs meeting the criteria for abnormality.  275 
 276 
Sample size calculation 277 
The sample size was based on an anticipated sensitivity of the index tests to 278 
detect POAG (based on current case definitions) of 0.7512 with a minimal 279 
acceptable precision of the sensitivity estimate of ±0.25 with 0.95 probability. 280 
This requires 42 POAG cases.  Since prevalence of suspected and definite 281 
POAG in the local elderly population would be approximately 10%26 it was 282 
estimated that at least 420 subjects needed to be recruited. 283 
 284 
Statistical analysis 285 
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Statistical analysis was performed using SPSS 21.0 software 286 
(www.ibm.com/SPSS_Statistics), Medcalc 14.8.1 (www.medcalc.org), and 287 
STATA 13.0 (StataCorp. 2013. College Station, TX: StataCorp LP, 288 
www.stata.com). Index data were analysed masked to findings from the 289 
reference ophthalmic examination. Unreliable results acquired by visual 290 
function tests (FDT and MMDT), and data from repeatedly poor quality ORA 291 
and OCT acquisitions were removed from analysis. The unit of analysis was 292 
the individual, and the comparison was between the most abnormal index test 293 
result from either the right or left eye and the overall reference standard 294 
classification.  295 
 296 
Differences in mean values for demographic characteristics between 297 
diagnostic groups were evaluated by ANOVA for normally distributed data, and 298 
Kruskal-Wallis test for data with skewed distributions, each together with post-299 
hoc analysis. For all tests, p<0.05 was considered statistically significant. Initial 300 
diagnostic accuracy estimates of each index test to detect glaucoma 301 
suspect/definite POAG combined and definite POAG were evaluated using the 302 
predefined cut-offs for abnormality to generate sensitivity, specificity and 303 
likelihood ratios with 95% confidence intervals. To compare index test 304 
performance within a clinically relevant range for detection of a low prevalence 305 
disease we determined the sensitivity at 90% specificity, and normalized the 306 
partial AUROC curves to determine the average sensitivity27 between 90% and 307 
100% specificity. To test for any statistically significant differences between 308 
sensitivity at set specificity, and partial AUROC curve estimates the Wald test 309 
was used.28 Best performing structural and functional criteria were combined in 310 
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series to calculate sensitivity and specificity values, and change from pre-test 311 
to post-test probability estimates of a given subject having POAG were 312 
determined using Bayesian reasoning.   313 
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Results 314 
 315 
505 subjects entered the study (59% female and 41% male), aged between 60 316 
and 92 years with median (interquartile range) age being 68 (59 to 77) years. 317 
Self-reported ethnicities were 88% White, 8% South Asian, 2% Black, 1% 318 
Chinese, and 1% ‘other’. Based on the reference standard examination, 26 319 
(5.1%) subjects were classified as definite POAG, 32 (6.4%) glaucoma 320 
suspect, and 17 (3.4%) OHT. Using Hodapp-Parrish-Anderson criteria,29 11 321 
(42%) definite POAG cases were classified as early, 6 (23%) as moderate and 322 
9 (35%) as advanced. Demographic and summary clinical data for each group 323 
are summarised in Table 2, available at www.aaojournal.org. A high proportion 324 
of subjects had ocular co-morbidities, including 9.5% with moderate or 325 
advanced AMD and 10.7% with clinically-significant cataract in one or both 326 
eyes. Following repeat examination, over 95% of results acquired using each 327 
of the four index tests were reliable or of sufficient quality for analysis (Table 1, 328 
available at www.aaojournal.org). 329 
 330 
Diagnostic performance of visual-function tests 331 
A FDT performance cut-off of 1 or more missed location at p<5% level of 332 
significance, representing the most common threshold for abnormality in 333 
published literature, yielded 72.4% (CI 59.8 to 82.3) sensitivity and 66.7 (CI 334 
62.1 to 71.0) specificity for detection of glaucoma suspect/POAG combined 335 
(Table 3). Using the same cut-off, sensitivity to detect POAG alone was 92.3% 336 
(CI 75.9 to 97.9) and specificity 65.2% (60.8 to 69.3). Test specificity improved 337 
to 79.1% (CI 75.2 to 82.5) using a test failure cut-off of 1 or more location(s) 338 
missed at p<1% level of significance, while retaining a sensitivity of 88.5% (CI 339 
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71.0 to 96.0) for POAG detection (Table 3). The developers’ recommended 340 
MMDT performance cut-off (global PTD 3.0) achieved test specificity of over 341 
80% but lower sensitivity of 51.7% (CI 39.2 to 64.1) for glaucoma 342 
suspect/POAG combined, and 65.4% (CI 46.2 to 80.6) for POAG detection. 343 
Notably, all (100%) cases of moderate and advanced POAG (mean deviation 344 
worse than -6dB) were detected by both perimetry index tests. Of the 11 345 
POAG subjects classified with early disease (-6dB or better), only 2 subjects 346 
(18%) were test positive using MMDT (global PTD 3.0), compared with 9 347 
subjects (82%) detected by the less specific FDT criterion (1 or more missed 348 
location at p<5% level of significance). 349 
 350 
Diagnostic performance of the SD-OCT 351 
Best performing parameters based on highest test sensitivity for detection of 352 
glaucoma suspect /POAG combined were GCC FLV (46.6%, CI 34.3 to 59.2), 353 
and inferior quadrant RNFL thickness (46.6%, CI 34.3 to 59.2). A similar trend 354 
followed for detection of POAG (GCC FLV 73.1%, CI 53.9 to 86.3; inferior 355 
quadrant thickness 76.9%, CI 57.9 to 89.0) (Table 3). Notably, all 5 GCC and 7 356 
RNFL parameters included for analysis individually provided a test specificity 357 
exceeding 90%. In particular, GCC GLV was 97.9% (CI 96.2 to 98.8) specific 358 
for discrimination of definite POAG, with the highest positive likelihood ratio of 359 
21.8 (CI 10.4 to 45.8) of all iVue parameters (Table 4, available at 360 
www.aaojournal.org). However, a threshold of abnormality defined by any of 361 
the 7 RNFL parameters exceeding the 99% normative level provided further 362 
diagnostic value by improving sensitivity to 62.1% (CI 49.2 to 73.4) for 363 
glaucoma suspect/POAG combined and 88.5% (CI 71.0 to 96.0) for POAG 364 
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while achieving specificity above 88%. Using the same cut-off, sensitivity 365 
improved to 93.3% (CI 70.2 to 98.8) for distinguishing POAG subjects with 366 
moderate and advanced POAG. Moreover, 25 of the 26 (96.1%, CI 81.1 to 367 
99.3) subjects classified as POAG in the reference ophthalmic examination 368 
were detected by one or more GCC or RNFL parameter exceeding the 99% 369 
normative interval (see Table 3) for a specificity of 81.3% (77.5 to 84.6).  370 
 371 
IOP estimates of IOPcc and IOPg generated by the ORA had little diagnostic 372 
value for distinguishing glaucoma suspect and POAG subjects from the rest of 373 
the sample. 374 
 375 
ROC analysis 376 
Sensitivity at 90% specificity, and partial AUROC curve for 90% to 100% 377 
specificity are summarized in Table 5 (see Table 6, available at 378 
www.aaojournal.org for data on total AUROC curves). Overall, inferior 379 
quadrant RNFL thickness measured using the iVue SD-OCT was best 380 
performing parameter, providing highest sensitivity (56.9%, CI 44.2 to 69.6 381 
glaucoma suspect/POAG combined; 82.8%, CI 67.6 to 97.9 POAG) and partial 382 
AUROC curve estimate (0.46, CI 0.34 to 0.58 glaucoma suspect/POAG 383 
combined; 0.70, CI 0.53 to 0.86 POAG) from 90% to 100% specificity. In fact, 384 
inferior quadrant RNFL thickness was statistically significantly superior to each 385 
of the visual function tests, based on partial AUROC curve estimates 386 
(glaucoma suspect/POAG combined FDT and MMDT p<0.001; POAG FDT 387 
and MMDT p<0.001) (Figure 2). Of the visual-function tests, FDT Patel et al. 388 
score (2000) achieved higher sensitivity (61.5%, CI 39.4 to 83.6) but a lower 389 
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partial AUROC curve result (0.35, CI 0.18 to 0.52) compared with MMDT 390 
global PTD (57.7%, CI 37.4 to 78.0 sensitivity, 0.44, CI 0.26 to 0.61 partial 391 
AUROC curve) for ranges starting from 90% specificity for distinguishing 392 
POAG from the rest of the sample, but these observations did not represent a 393 
statistically significant difference (sensitivity at set specificity p=0.598, partial 394 
AUROC curve p=0.248) (Figure 2). 395 
 396 
Combining index test results  397 
The combination of inferior quadrant RNFL thickness (p<1%) with FDT (1 or 398 
more location(s) missed at p<5% level) in which failure of either test is 399 
indicative of abnormality achieves a sensitivity of 79.3% (CI 67.2 to 87.7) for 400 
glaucoma suspect/POAG combined and 100.0% (CI 87.1 to 100.0) for POAG 401 
detection but with a marked reduction in specificity (glaucoma suspect/ POAG 402 
combined 63.3, CI 58.9 to 67.6; POAG 65.2, CI 60.7 to 69.5). On the other 403 
hand, stipulating that failure of both tests was indicative of POAG improved 404 
specificity to 96.8% (CI 94.8 to 98.1), but this did not represent a statistically 405 
significant improvement above test specificity of 95.0% (CI 92.6 to 96.6) 406 
achieved by inferior quadrant thickness alone (McNemar, p=1.0). Notably, the 407 
combination of iVue SD-OCT RNFL inferior quadrant parameter (p<1%) with 408 
FDT (1 or more missed location at p<5% level) detected all 26 subjects 409 
classified as POAG (Figure 3, available at www.aaojournal.org). 410 
 411 
To further evaluate the diagnostic value of combining index test data using 412 
Bayesian probabilistic reasoning, best-performing parameters and cut-offs for 413 
abnormality were selected using the highest positive likelihood ratios (Table 4, 414 
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available at www.aaojournal.org). The probability estimate of a given subject 415 
having POAG rose from 5% (pre-test probability) to over 85% (post-test 416 
probability) when visual function tests (FDT, 1 or more missed location at 417 
p<1% level or MMDT, global PTD 3.0) were combined in series with best 418 
performing structural parameters (RNFL inferior quadrant thickness or GCC 419 
GLV, p<1%), and ORA IOPcc (>21mmHg). Using these test cut-offs, a post-420 
test probability over 90% was achieved for detection of glaucoma 421 
suspect/POAG combined, rising from a pre-test probability of 11.5%.  422 
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Discussion 423 
Currently, a national population-based screening programme for OAG has not 424 
been implemented in any country. An economic modeling study undertaken in 425 
Finland determined that an organized screening programme for glaucoma 426 
could be a cost-effective strategy compared to opportunistic case-finding, 427 
especially in older age groups.30 A UK-based study using a similar approach to 428 
evaluate the clinical and cost-effectiveness of screening for POAG proposed 429 
the use of tonometry combined with an initial technology-based assessment, 430 
which would allow an enriched population to be referred for an office-based 431 
assessment by an ophthalmologist.11 Alternatively, clinical data collected from 432 
a technology-based assessment could be transferred digitally and evaluated in 433 
a virtual clinic by a glaucoma specialist to improve the positive predictive value 434 
of referrals for further ophthalmic investigation.31, 32 Cost-effectiveness may be 435 
improved by implementing a screening programme that targeted a number of 436 
sight-threatening eye diseases. 437 
 438 
The current study evaluated the diagnostic performance of structural and 439 
visual function tests for the detection of glaucoma in a population of elderly 440 
subjects, representative of the target population for screening, in which 441 
pathologies other than glaucoma may be present. Data were analyzed using 442 
the individual as the unit of analysis. The performance of the FDT using the 443 
C20-5 screening program was similar to that reported in previous population 444 
screening studies.33, 34 However, there has only been one published diagnostic 445 
accuracy study evaluating the MMDT.35 This study found sensitivities and 446 
specificities of greater than 85%. It is likely that the lower performance of the 447 
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MMDT in the current study relates to the high levels of ocular co-morbidity 448 
typical of an elderly population, which may have impacted on the overall 449 
performance of the vision-function tests. ROC analysis of the FDT and MMDT, 450 
based on sensitivities at set specificities and partial AUROC, showed no 451 
statistical difference in performance between the two tests for the detection of 452 
POAG. However, in view of the MMDTs greater portability, ease of use and 453 
relatively lower cost it warrants further evaluation in population studies to 454 
further determine its potential as a screening test for glaucoma. 455 
 456 
The iVue OCT is a recently developed compact SD-OCT and this is the first 457 
study to investigate its diagnostic performance for glaucoma detection using its 458 
in-built normative database. The structural parameters selected for the 459 
analysis and associated pass-fail criteria (value outside the 99% confidence 460 
interval) were established a priori. The best performing individual structural 461 
parameter (inferior quadrant RNFL thickness) provided a sensitivity of over 462 
75% with a specificity of 95%, which may reflect the vulnerability of the inferior 463 
quadrant of the optic disc to glaucomatous damage.36, 37 The OCT was 464 
particularly effective in identifying subjects with glaucoma, for example using a 465 
criterion of any structural parameter at the p<1% level the OCT would have 466 
identified 25 of 26 glaucoma subjects in our sample. ORA-derived IOP 467 
estimates were of limited diagnostic value in our population as half of the 26 468 
glaucoma subjects were already receiving IOP-lowering therapy or had 469 
previously undergone surgical or laser interventions.  470 
 471 
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Early detection and treatment of glaucoma reduces the rate of progression of 472 
glaucomatous vision loss and visual field defects,38, 39 which is likely to result in 473 
a better health-related quality of life for those affected, but concerns have been 474 
raised as to the potential overtreatment of individuals who may not be at 475 
significant risk of developing advanced glaucoma and visual impairment in 476 
their lifetime.11  A retrospective UK study using a large visual field dataset, and 477 
modelling projected field loss in the patients’ remaining lifetime, determined 478 
that only 5.2% of patients were at risk of progressing to statutory blindness in 479 
both eyes; more  than 90% of these had a visual field mean deviation worse 480 
than -6dB in one or both eyes at presentation.40 Given that the likelihood of 481 
patients suffering significant visual impairment is linked to the level of VF loss 482 
at presentation, it is notable that 100% of those in the current study with 483 
moderate or advanced glaucoma (mean deviation worse than -6dB) were 484 
detected by either the FDT (p<5% level), or the MMDT (global PTD 3.0).  485 
 486 
The natural history of glaucoma means that in some people with early disease, 487 
structural changes precede functional loss, whilst in others functional 488 
abnormalities may be observed before detectable changes in structural 489 
parameters.41 In the current study, thirty-two subjects fell into either category 490 
and were classified as ‘glaucoma suspects’. Differentiating between suspects 491 
and normals presents a significant clinical challenge, as there is a substantial 492 
overlap of clinical characteristics between the groups. All four index tests 493 
showed poorer discrimination between normal subjects and POAG/glaucoma 494 
suspect groups combined than between those with confirmed glaucoma and 495 
the rest of the sample. The detection of glaucoma suspects requires a case 496 
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definition based on failure on either a structural or functional test. Whilst this 497 
strategy is likely to improve sensitivity it is generally at the expense of 498 
specificity. An alternative case-finding strategy is to use a Bayesian reasoning 499 
approach.  In clinical practice, a clinician will intuitively integrate the results of 500 
diagnostic tests together with an estimate of the patient’s pre-test probability of 501 
disease based on age, IOP and family history of glaucoma to estimate an 502 
individual’s post-test probability. The probability of disease can be formally 503 
estimated by calculations using the likelihood ratios of the diagnostic tests. The 504 
results of independent tests can be combined in series to revise post-test 505 
probability estimates.42 However, the lack of true independence between 506 
structural and functional criteria may lead to an overestimation of the combined 507 
post-test probability. Nevertheless, this Bayesian approach could be used to 508 
develop diagnostic algorithms and has great potential for glaucoma case-509 
finding or population screening pathways.43  510 
 511 
The present study had a number of strengths: the design, analysis and 512 
reporting complied with the principles of the STARD statement14 and to reduce 513 
spectrum bias the target population included consecutive subjects who met the 514 
inclusion criteria. Although it is possible that higher numbers of those with 515 
previous or family ocular history were more likely to volunteer and agree to 516 
participate in the study, the prevalence of OAG in our population (5%) was 517 
comparable with that expected for the age demographic. Furthermore, a wide 518 
spectrum of disease severity was identified. We therefore feel the population is 519 
likely to be broadly representative of those presenting for glaucoma case-520 
finding in the community. The reference standard for OAG corresponded to 521 
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that used in a typical hospital glaucoma unit and was based on the results of a 522 
standard ophthalmic examination by a validated clinician. At the present time, 523 
this examination represents the clinical reference standard for OAG, but as 524 
evidence accumulates it is anticipated that OCT may become part of this 525 
standard in the future. All index tests and the reference standard examination 526 
were undertaken on the same day, and the clinicians performing the reference 527 
and index tests were masked to the outcome of either. The study also has 528 
some limitations. The sample size of 505 subjects provided only 26 glaucoma 529 
subjects.  This resulted in wide confidence intervals around our diagnostic 530 
sensitivity estimates, which may have masked real differences between index 531 
tests. Furthermore, almost 90% of our study population was of White European 532 
origin suggesting our findings may not be generalizable to other ethnic groups 533 
where glaucoma is more prevalent (e.g. subjects of Black origin).  Data 534 
collection for this study was undertaken in dedicated research rooms based in 535 
a community eye clinic. In a real-world clinic setting, equipment may not be 536 
calibrated routinely and it is anticipated that diagnostic performance may be 537 
less good. Nevertheless, this study provides useful data to inform the 538 
development of further larger multi-center glaucoma screening studies. 539 
 540 
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Legends for Figures 1 and 2 549 
 550 
Figure 1:  Study flow diagram. FDT = frequency doubling technology perimeter; 551 
MMDT = Moorfields motion displacement test; SD-OCT = spectral domain 552 
optical coherence tomographer; ORA = ocular response analyzer; POAG = 553 
primary open angle glaucoma; OHT = ocular hypertension.  554 
 555 
Figure 2:  Index test diagnostic effectiveness comparisons using ROC curves 556 
with sensitivity at set specificity estimates and associated 95% confidence 557 
intervals for detection of glaucoma suspect/POAG (primary open angle 558 
glaucoma) combined (a) and POAG (b). FDT = Frequency Doubling 559 
Technology Perimeter; MMDT = Moorfields motion displacement threshold 560 
test; RNFL = retinal nerve fibre layer thickness. 561 
  562 
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